Status:
UNKNOWN
Combined Treatment With CO2 Laser and Isotretinoin for Acne Scars
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Acne Vulgaris
Eligibility:
All Genders
15-60 years
Phase:
PHASE2
Brief Summary
Isotretinoin is an FDA-approved vitamin A metabolite for the treatment of severe acne; acne that does not respond to other treatments and has a tendency to cause scarring. Ablative laser treatment is...
Detailed Description
Patients treated with Isotretinoin for at least 2 months with doses ranging from 20 mg-40 mg per day were treated with Co2 ablative laser on one side of the face (randomized). Patients will be treated...
Eligibility Criteria
Inclusion
- Healthy individuals
- Age 15-60 years old
- Male/Female
- Acne moderate to severe with scarring
- Finished at least 2 months of treatment with Isotretinoin
Exclusion
- Prior laser treatment for acne scarring
- Patients that have a tendency to have abnormal scarring
- Patients that are immunosuppressed or patients receiving immunosuppressive treatment
- Prior radiotherapy treatment to affected area
- Infected acne
- Rosacea
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04870489
Start Date
November 1 2017
End Date
June 1 2022
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv sourasky medical center
Tel Aviv, Israel